Showing 1291-1300 of 1963 results for "".
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://modernaesthetics.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- AAD 2026: Allergan Aesthetics Highlights TrenibotE Data and GLP-1 RA Patient Trendshttps://modernaesthetics.com/news/aad-2026-allergan-aesthetics-highlights-trenibote-data-and-glp-1-patient-trends/2486432/Allergan Aesthetics, an AbbVie company, presented four posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, including new findings on repeat treatment with investigational trenibotulinumtoxinE (TrenibotE) and insights into aesthetic trends among patients r
- AAD 2026: Acclaro to Highlight Expanding Clinical Uses of UltraClear 2910 nm Fiber Laserhttps://modernaesthetics.com/news/aad-2026-acclaro-to-highlight-expanding-clinical-uses-of-ultraclear-2910-nm-fiber-laser/2486381/Emerging clinical data on Acclaro’s UltraClear® 2910 nm fiber laser is set to be presented during multiple sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado from March 26 through 31. The technology, a cold ablative fiber lase
- Aesthetic Sequelae of GLP-1 Receptor Agonists Highlighted in Clinical Reviewhttps://modernaesthetics.com/news/aesthetic-sequelae-of-glp-1-receptor-agonists-highlighted-in-clinical-review/2485615/Dermatologists are increasingly encountering aesthetic complications associated with GLP-1 receptor agonist (RA)–induced weight loss, according to a clinical review presented at the South Beach Symposium. The poster, b
- Injectable Skin Boosters Market Set to Exceed $3.2 Billion by 2032, Driven by HA-Based Rejuvenation Trendshttps://modernaesthetics.com/news/injectable-skin-boosters-market-set-to-exceed-32-billion-by-2032-driven-by-ha-based-rejuvenation-trends/2485495/The global market for injectable skin boosters is projected to more than double over the next decade, climbing from $1,492.17 million in 2025 to an estimated $3,263.80 million by 2032, according to new data from MMR Statistics. This represents a compound annual gro
- ODAC 2026 Adds Hands-On, High-Impact Workshopshttps://modernaesthetics.com/news/odac-2026-adds-hands-on-high-impact-workshops/2484689/The ODAC Dermatology Conference will return to Orlando, Florida, in 2026 with a refreshed slate of interactive, expert-led sessions that emphasize skill-building across medical, surgical, and aesthetic dermatology, organizers said in a press release. Scheduled for J
- AAFPRS Highlights Energy-Based Device Trends Defining Aesthetic Advancements in 2025https://modernaesthetics.com/news/aafprs-highlights-energy-based-device-trends-defining-aesthetic-advancements-in-2025/2484060/The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) is spotlighting the latest innovations in energy-based devices (EBDs), signaling a shift toward increasingly personalized, nonsurgical facial rejuvenation in 2025.
- SkinMedica Updates Packaging, Launches New HA5 Moisturizerhttps://modernaesthetics.com/news/skinmedica-updates-packaging-launches-new-ha5-moisturizer/2483916/Allergan Aesthetics, a division of AbbVie, announced a comprehensive redesign of its SkinMedica® product packaging aimed at improving user experience and reducing environmental impact. The updated packaging includes a modernized logo, copper accents, and simplified
- Study Finds Abdominoplasty Can Help Improve Urinary Incontinence Symptomshttps://modernaesthetics.com/news/study-finds-abdominoplasty-can-help-improve-urinary-incontinence-symptoms/2483374/A new study published in Aesthetic Plastic Surgery reports that abdominoplasty may contribute to improvement in urinary incontinence symptoms. The study titled “Can Abdominoplasty Relieve Symptoms of Urinary Incontinence?” systematically reviewed the existing literature to evaluate the f
- Oral GLP-1 Hits Phase 3 Trial Targets; Regulatory Submissions Cominghttps://modernaesthetics.com/news/oral-glp-1-hits-phase-3-trial-targets-regulatory-submissions-coming/2483149/Eli Lilly and Company announced positive topline results from its Phase 3 ATTAIN-2 trial, showing that its investigational oral GLP-1 receptor agonist, orforglipron, achieved significant weight loss and improved cardiometabolic outcomes in adults with obesity or overweight status and type 2 diabe